Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

603 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase III trial of retinoic acid and arsenic trioxide versus retinoic acid and chemotherapy in patients with acute promyelocytic leukemia: health-related quality-of-life outcomes.
Efficace F, Mandelli F, Avvisati G, Cottone F, Ferrara F, Di Bona E, Specchia G, Breccia M, Levis A, Sica S, Finizio O, Kropp MG, Fioritoni G, Cerqui E, Vignetti M, Amadori S, Schlenk RF, Platzbecker U, Lo-Coco F. Efficace F, et al. Among authors: platzbecker u. J Clin Oncol. 2014 Oct 20;32(30):3406-12. doi: 10.1200/JCO.2014.55.3453. Epub 2014 Sep 22. J Clin Oncol. 2014. PMID: 25245446 Clinical Trial.
Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia.
Platzbecker U, Thiede C, Füssel M, Geissler G, Illmer T, Mohr B, Hänel M, Mahlberg R, Krümpelmann U, Weissinger F, Schaich M, Theuser C, Ehninger G, Bornhäuser M. Platzbecker U, et al. Leukemia. 2006 Apr;20(4):707-14. doi: 10.1038/sj.leu.2404143. Leukemia. 2006. PMID: 16482208 Clinical Trial.
Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group.
Lübbert M, Suciu S, Baila L, Rüter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW. Lübbert M, et al. Among authors: platzbecker u. J Clin Oncol. 2011 May 20;29(15):1987-96. doi: 10.1200/JCO.2010.30.9245. Epub 2011 Apr 11. J Clin Oncol. 2011. PMID: 21483003 Clinical Trial.
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia.
Ottone T, Cicconi L, Hasan SK, Lavorgna S, Divona M, Voso MT, Montefusco E, Melillo L, Barragán E, Platzbecker U, Giannì L, Hubmann M, Pagoni M, Amadori S, Lo-Coco F. Ottone T, et al. Among authors: platzbecker u. Leuk Res. 2012 Apr;36(4):474-8. doi: 10.1016/j.leukres.2011.10.015. Epub 2011 Nov 8. Leuk Res. 2012. PMID: 22071137
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lübbert M, Hänel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Döhner K, Sauer M, Ganser A, Amadori S, Mandelli F, Döhner H, Ehninger G, Schlenk RF, Platzbecker U; Gruppo Italiano Malattie Ematologiche dell'Adulto; German-Austrian Acute Myeloid Leukemia Study Group; Study Alliance Leukemia. Lo-Coco F, et al. Among authors: platzbecker u. N Engl J Med. 2013 Jul 11;369(2):111-21. doi: 10.1056/NEJMoa1300874. N Engl J Med. 2013. PMID: 23841729 Free article. Clinical Trial.
Treatment of acute promyelocytic leukemia.
Lo-Coco F, Orlando SM, Platzbecker U. Lo-Coco F, et al. Among authors: platzbecker u. N Engl J Med. 2013 Oct 10;369(15):1472. doi: 10.1056/NEJMc1309895. N Engl J Med. 2013. PMID: 24106948 No abstract available.
Preference for involvement in treatment decisions and request for prognostic information in newly diagnosed patients with higher-risk myelodysplastic syndromes.
Efficace F, Gaidano G, Sprangers M, Cottone F, Breccia M, Voso MT, Caocci G, Stauder R, Di Tucci AA, Sanpaolo G, Selleslag D, Angelucci E, Platzbecker U, Mandelli F. Efficace F, et al. Among authors: platzbecker u. Ann Oncol. 2014 Feb;25(2):447-54. doi: 10.1093/annonc/mdt557. Ann Oncol. 2014. PMID: 24478321 Free article.
Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes.
Efficace F, Gaidano G, Breccia M, Criscuolo M, Cottone F, Caocci G, Bowen D, Lübbert M, Angelucci E, Stauder R, Selleslag D, Platzbecker U, Sanpaolo G, Jonasova A, Buccisano F, Specchia G, Palumbo GA, Niscola P, Wan C, Zhang H, Fenu S, Klimek V, Beyne-Rauzy O, Nguyen K, Mandelli F. Efficace F, et al. Among authors: platzbecker u. Br J Haematol. 2015 Feb;168(3):361-70. doi: 10.1111/bjh.13138. Epub 2014 Oct 1. Br J Haematol. 2015. PMID: 25272332 Free article.
Two cycles of risk-adapted consolidation therapy in patients with acute promyelocytic leukemia. Results from the SAL-AIDA2000 trial.
Röllig C, Schäfer-Eckardt K, Hänel M, Kramer M, Schaich M, Thiede C, Oelschlägel U, Mohr B, Wagner T, Einsele H, Krause SW, Bodenstein H, Martin S, Stuhlmann R, Ho AD, Bornhäuser M, Ehninger G, Schuler U, Platzbecker U. Röllig C, et al. Among authors: platzbecker u. Ann Hematol. 2015 Apr;94(4):557-63. doi: 10.1007/s00277-014-2242-6. Epub 2014 Nov 5. Ann Hematol. 2015. PMID: 25366167 Clinical Trial.
603 results